# US 2024/0115738 A1 · Methods and compositions for treatment of cystic fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0115738 A1
- Document ID: US20240115738A1
- Status: Published application
- Kind: A1
- Application number: 18/285,560
- Filed: 2022-04-15
- Published: 2024-04-11
- Earliest claimed: 2021-04-15
- Assignees: Spirovant Sciences, Inc.
- Applicants: Spirovant Sciences, Inc.
- Inventors: Mark SMITH; Katherine EXCOFFON; Shen LIN; Madhupriya MAHANKALI; Eric YUEN; Roland KOLBECK; Matthew GLATFELTER
- Web page: https://patentgrep.com/patent/US20240115738A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 35/761: Adenovirus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 11/00: Drugs for disorders of the respiratory system
- C12N 15/86: Viral vectors
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C07K 14/47: from mammals
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods for treatment of cystic fibrosis (CF), including for patients with class I CFTR mutations. The methods may involve administration of a recombinant adeno-associated virus (rAAV) that includes an AV.TL65 capsid protein and a polynucleotide that includes an F5 enhancer and a tg83 promoter operably linked to a CFTRΔR minigene, or a pharmaceutical composition thereof.

## Claims

### Claim 1

A method of treating cystic fibrosis (CF) in a subject whose genotype comprises at least one class I CFTR mutation, the method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) comprising (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.

### Claim 2

A method of treating CF in a subject lacking CFTR protein, the method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) comprising (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject's genotype comprises at least one class I CFTR mutation.

### Claim 4 (depends on 1, 3)

The method of claim 1 or 3, wherein the at least one class I CFTR mutation is a nonsense mutation, a splice mutation, or a deletion.

### Claim 5 (depends on 1, 3)

The method of any one of claims 1, 3, and 4, wherein the at least one class I CFTR mutation comprises a Q2X mutation, a S4X mutation, a W19X mutation, a G27X mutation, a Q39X mutation, a W57X mutation, a E60X mutation, a R75X mutation, a L88X mutation, a E92X mutation, a Q98X mutation, a Y122X mutation, a E193X mutation, a W216X mutation, a L218X mutation, a Q220X mutation, a Y275X mutation, a C276X mutation, a Q290X mutation, a G330X mutation, a W401X mutation, a Q414X mutation, a S434X mutation, a S466X mutation, a S489X mutation, a Q493X mutation, a W496X mutation, a C524X mutation, a Q525X mutation, a G542X mutation, a G550X mutation, a Q552X mutation, a R553X mutation, a E585X mutation, a G673X mutation, a Q685X mutation, a R709X mutation, a K710X mutation, a Q715X mutation, a L732X mutation, a R764X mutation, a R785X mutation, a R792X mutation, a E822X mutation, a W882X mutation, a W846X mutation, a Y849X mutation, a R851X mutation, a Q890X mutation, a S912X mutation, a Y913X mutation, a Q1042X mutation, a W1089X mutation, a Y1092X mutation, a W1098X mutation, a R1102X mutation, a E1104X mutation, a W1145X mutation, a R1158X mutation, a R1162X mutation, a S1196X mutation, a W1204X mutation, a L1254X mutation, a S1255X mutation, a W1282X mutation, a Q1313X mutation, a Q1330X mutation, a E1371X mutation, a Q1382X mutation, a Q1411X mutation, a 2116delCTAA mutation, or a combination thereof.

### Claim 6 (depends on 1, 3, 4, 5)

The method of any one of claims 1 and 3-5, wherein the subject's genotype comprises two class I CFTR mutations.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject's genotype comprises a W1282X mutation and a R1162X mutation.

### Claim 8

A method of treating CF in a subject whose genotype comprises at least one class III CFTR mutation, the method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) comprising (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the at least one class III CFTR mutation comprises a G551 D mutation or a S549N mutation.

### Claim 10 (depends on 8, 9)

The method of claim 8 or 9, wherein the subject's genotype comprises two class III CFTR mutations.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, further comprising administering to the subject a therapeutically effective amount of an augmenter of AAV transduction.

### Claim 12 (depends on 11)

The method of claim 11, wherein the augmenter is administered to the subject within about 48 h following administration of the rAAV.

### Claim 13

A method of treating CF in a subject, the method comprising:
(a) administering to the subject a therapeutically effective amount of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof; and
(b) administering to the subject a therapeutically effective amount of an augmenter of AAV transduction within about 48 h following administration of the rAAV.

### Claim 14

A method of treating CF in a subject, the method comprising administering to the subject a therapeutically effective amount of an augmenter of AAV transduction, wherein the augmenter is administered to the subject within about 48 h following administration of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12-14, wherein the augmenter is administered to the subject within about 24 h following administration of the rAAV.

### Claim 16 (depends on 15)

The method of claim 15, wherein the augmenter is administered to the subject within about 12 h following administration of the rAAV.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The method of any one of claims 11-16, wherein the augmenter is an anthracycline, a proteasome inhibitor, a tripeptidyl aldehyde, or a combination thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the anthracycline is doxorubicin, idarubicin, aclarubicin, daunorubicin, epirubicin, valrubicin, mitoxantrone, or a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the anthracycline is doxorubicin, idarubicin, or a combination thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the anthracycline is doxorubicin.

### Claim 21 (depends on 17)

The method of claim 17, wherein the proteasome inhibitor is bortezomib, carfilzomib, and ixazomib.

### Claim 22 (depends on 17)

The method of claim 17, wherein the tripeptidyl aldehyde is N-acetyl-1-leucyl-1-leucyl-1-norleucine (LLnL).

### Claim 23 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 13-22, wherein the subject lacks CFTR protein.

### Claim 24 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 13-23, wherein the subject's genotype comprises at least one class I CFTR mutation.

### Claim 25 (depends on 24)

The method of claim 24, wherein the at least one class I CFTR mutation is a nonsense mutation, a splice mutation, or a deletion.

### Claim 26 (depends on 24, 25)

The method of claim 24 or 25, wherein the at least one class I CFTR mutation comprises a Q2X mutation, a S4X mutation, a W19X mutation, a G27X mutation, a Q39X mutation, a W57X mutation, a E60X mutation, a R75X mutation, a L88X mutation, a E92X mutation, a Q98X mutation, a Y122X mutation, a E193X mutation, a W216X mutation, a L218X mutation, a Q220X mutation, a Y275X mutation, a C276X mutation, a Q290X mutation, a G330X mutation, a W401X mutation, a Q414X mutation, a S434X mutation, a S466X mutation, a S489X mutation, a Q493X mutation, a W496X mutation, a C524X mutation, a Q525X mutation, a G542X mutation, a G550X mutation, a Q552X mutation, a R553X mutation, a E585X mutation, a G673X mutation, a Q685X mutation, a R709X mutation, a K710X mutation, a Q715X mutation, a L732X mutation, a R764X mutation, a R785X mutation, a R792X mutation, a E822X mutation, a W882X mutation, a W846X mutation, a Y849X mutation, a R851X mutation, a Q890X mutation, a S912X mutation, a Y913X mutation, a Q1042X mutation, a W1089X mutation, a Y1092X mutation, a W1098X mutation, a R1102X mutation, a E1104X mutation, a W1145X mutation, a R1158X mutation, a R1162X mutation, a S1196X mutation, a W1204X mutation, a L1254X mutation, a S1255X mutation, a W1282X mutation, a Q1313X mutation, a Q1330X mutation, a E1371X mutation, a Q1382X mutation, a Q1411X mutation, a 2116delCTAA mutation, or a combination thereof.

### Claim 27 (depends on 24, 25, 26)

The method of any one of claims 24-26, wherein the subject's genotype comprises two class I CFTR mutations.

### Claim 28 (depends on 27)

The method of claim 27, wherein the subject's genotype comprises a W1282X mutation and a R1162X mutation.

### Claim 29 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 13-26, wherein the subject's genotype comprises at least one class II CFTR mutation, at least one class III CFTR mutation, at least one class IV CFTR mutation, at least one class V CFTR mutation, at least one class VI CFTR mutation, or at least one class VII CFTR mutation.

### Claim 30 (depends on 29)

The method of claim 29, wherein the subject's genotype comprises two class II CFTR mutations, two class III CFTR mutations, two class IV CFTR mutations, two class V CFTR mutations, two class VI CFTR mutations, or two class VII CFTR mutations.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the rAAV comprises an AV.TL65 capsid protein.

### Claim 32 (depends on 31)

The method of claim 31, wherein the AV.TL65 capsid protein comprises the amino acid sequence of SEQ ID NO:13.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, wherein the polynucleotide comprises an F5 enhancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the F5 enhancer comprises the polynucleotide sequence of SEQ ID NO:1.

### Claim 35 (depends on 33)

The method of claim 33, wherein the F5 enhancer comprises the polynucleotide sequence of SEQ ID NO:14.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the polynucleotide comprises a tg83 promoter.

### Claim 37 (depends on 36)

The method of claim 36, wherein the tg83 promoter comprises the polynucleotide sequence of SEQ ID NO:2.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein the CFTRΔR minigene is a human CFTRΔR minigene.

### Claim 39 (depends on 38)

The method of claim 38, wherein the human CFTRΔR minigene is encoded by a polynucleotide comprising the sequence of SEQ ID NO:4.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1-39, wherein the polynucleotide comprises, in a 5′-to-3′ direction, the F5 enhancer, the tg83 promoter, and the CFTRΔR minigene.

### Claim 41 (depends on 40)

The method of claim 40, wherein the polynucleotide comprises the sequence of SEQ ID NO:7.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, further comprising administering one or more additional therapeutic agents to the subject.

### Claim 43 (depends on 42)

The method of claim 42, wherein the one or more additional therapeutic agents includes an antibiotic, a mucus thinner, a CFTR modulator, a mucolytic, normal saline, hypertonic saline, an immunosuppressive agent, or a combination thereof.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 1-43, wherein the administering is by inhalation, nebulization, aerosolization, intranasally, intratracheally, intrabronchially, orally, intravenously, subcutaneously, or intramuscularly.

### Claim 45 (depends on 44)

The method of claim 44, wherein the administering is by inhalation, nebulization, aerosolization, intranasally, intratracheally, and/or intrabronchially.

### Claim 46 (depends on 45)

The method of claim 45, wherein the administering is by inhalation.

### Claim 47

An rAAV for use in treating CF in a subject whose genotype comprises at least one class I CFTR mutation, wherein the rAAV comprises (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.

### Claim 48

An rAAV for use in treating CF in a subject lacking CFTR protein, wherein the rAAV comprises (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.

### Claim 49

An rAAV for use in treating CF in a subject whose genotype comprises at least one class III CFTR mutation, wherein the rAAV comprises (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.

### Claim 50

An rAAV for use in a method of treating CF in a subject, the method comprising:
(a) administering to the subject a therapeutically effective amount of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof; and
(b) administering to the subject a therapeutically effective amount of an augmenter of AAV transduction within about 48 h following administration of the rAAV.

### Claim 51

An augmenter of AAV transduction for use in treating CF in a subject, wherein the augmenter is administered to the subject within about 48 h following administration of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof; and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
